José Dario Portillo-Miño , David Bettin-Gonzalez , Franco Andrés Montenegro Coral
{"title":"mRNA vaccines in gastric cancer: How close are we?","authors":"José Dario Portillo-Miño , David Bettin-Gonzalez , Franco Andrés Montenegro Coral","doi":"10.1016/j.vacun.2023.10.006","DOIUrl":null,"url":null,"abstract":"<div><p>Gastric cancer (GC) is one of the neoplasms with higher mortality, causing around 700 000 deaths worldwide. Despite efforts in GC research, chemotherapy, radiotherapy<span><span>, and conventional surgery have not been sufficiently effective. Immunotherapy<span><span> has been proposed as an alternative, and the most recent guidelines recommend its use as a third-line treatment for advanced GC. In this context, the development of an </span>mRNA vaccine to control GC is presented as a promising alternative, either to stimulate an immune response against tumor cells or as a therapeutic option to restore the immune system and reduce mortality from GC. Although there is still a long way to go, technological advances and ongoing research bring us closer to the development of an mRNA vaccine for GC that can be administered in combination with </span></span>immune checkpoint inhibitors.</span></p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988723001012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Gastric cancer (GC) is one of the neoplasms with higher mortality, causing around 700 000 deaths worldwide. Despite efforts in GC research, chemotherapy, radiotherapy, and conventional surgery have not been sufficiently effective. Immunotherapy has been proposed as an alternative, and the most recent guidelines recommend its use as a third-line treatment for advanced GC. In this context, the development of an mRNA vaccine to control GC is presented as a promising alternative, either to stimulate an immune response against tumor cells or as a therapeutic option to restore the immune system and reduce mortality from GC. Although there is still a long way to go, technological advances and ongoing research bring us closer to the development of an mRNA vaccine for GC that can be administered in combination with immune checkpoint inhibitors.
期刊介绍：
Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
